Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: hepatitis C therapeutics - Dynavax

Next Previous
Drug Profile

Research programme: hepatitis C therapeutics - Dynavax

Alternative Names: Hepatitis C immunostimulatory DNA therapy

Latest Information Update: 13 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dynavax Technologies
  • Developer Dynavax Technologies; Symphony Dynamo
  • Class Oligonucleotides
  • Mechanism of Action Th1 cell stimulants; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 10 Feb 2026 Dynavax Technologies has been acquired by Sanofi
  • 18 Apr 2012 No development reported - Preclinical for Hepatitis C in USA (unspecified route)
  • 16 Apr 2008 Preclinical trials in Hepatitis C in USA (unspecified route)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top